Industries / Health / Healthcare / Pharmacy / Specialty pharmacy
Who may fill a drug
This is the work of deciding which pharmacies may stock and dispense a specialty drug, done by drug makers through limited distribution (selling a drug to only a few chosen pharmacies), by payers and PBMs through their pharmacy networks, by accreditors, by courts and lawmakers, and in many countries by hospitals.
7
Milestones achieved, from 1996 to 2025.
1
To watch for: announced, not yet confirmed outside.
2
Open deliverables. Nobody has shipped them.
The road
AchievedWatch forOpen
Achieved
1996
A maker picks its pharmacy
Accredo's 1998 prospectus describes an agreement with Biogen, running for three years to May 1999, for Avonex, a once-a-week injection for multiple sclerosis. Accredo was Biogen's only preferred home-delivery pharmacy for the drug, outside Medicaid in some states, and in return could not sell competing multiple sclerosis drugs without Biogen's approval. Biogen kept the right to appoint other pharmacies.
LessonThe pharmacy's place in the network was bought with a promise not to sell the maker's rivals.
Credit
Biogen; Accredo
2005
A PBM buys Accredo
A pharmacy benefit manager (PBM) is the firm that runs drug benefits for health plans and employers and decides which pharmacies are in their networks. On 18 August 2005 Medco, one of the largest US PBMs, completed its $2.3 billion purchase of Accredo, creating what it called the nation's largest specialty pharmacy business, with more than $4 billion a year in revenue. From then on, companies that set pharmacy networks also owned specialty pharmacies inside them.
Credit
Medco Health Solutions; Accredo Health
2015
Hospital drugs reach local pharmacies
Australia's section 100 Highly Specialised Drugs Program gives access to specialised medicines for chronic conditions under the Pharmaceutical Benefits Scheme (PBS), with limits on where they may be prescribed and supplied: by approved public and private hospital authorities and pharmacists. Community Access arrangements introduced on 1 July 2015 let community pharmacists dispense a listed group of them, including HIV and hepatitis B medicines and maintenance clozapine, wherever they were prescribed.
Credit
Australian Government Department of Health
2017
Accreditation becomes the entry ticket
Accreditation is a review of a pharmacy's processes by an independent body such as URAC or ACHC. Drug Channels Institute counted 729 accredited specialty pharmacy locations at the end of 2017, almost double the 2015 figure. URAC's director of pharmacy, Heather Bonome, said many pharmacies came to it because a drug maker or payer had made accreditation a requirement to do business within its limited-distribution network. The article reported that fees for first and renewal inspections were often the biggest obstacle for smaller pharmacies.
Credit
URAC; ACHC; Drug Channels Institute (Adam Fein)
2023
Makers may limit 340B pharmacies
340B is a US federal program under which drug makers sell at deep discounts to clinics and hospitals that serve many low-income patients. HHS guidance allowed each such clinic one outside "contract pharmacy" in 1996 and any number in 2010, after which their number grew twentyfold. In 2020 drug makers including Sanofi, Novo Nordisk and AstraZeneca began limiting discounted shipments, typically to one contract pharmacy for a clinic with no pharmacy of its own. On 30 January 2023 the Third Circuit ruled that the law does not require makers to deliver to an unlimited number of contract pharmacies, and on 21 May 2024 the D.C. Circuit held that makers may set conditions on distribution, while leaving room to challenge more onerous ones. US only.
Credit
Judge Bibas for the Third Circuit; Judge Katsas for the D.C. Circuit
2023
Texas limits forced white bagging
White bagging is when a health plan makes a clinic get a drug it will inject or infuse from a specialty pharmacy the plan chooses, which ships it to the clinic for that one patient, instead of the clinic buying and stocking it; brown bagging is when the drug is shipped to the patient, who carries it in. Texas House Bill 1647, passed 139 to 1 and 31 to 0 and in force for plans issued or renewed from 1 January 2024, bars state-regulated health plans from requiring that such drugs come only from certain pharmacies, for patients with chronic, complex, rare or life-threatening conditions, when the doctor finds that a delay would likely worsen the disease or that using the plan's pharmacy would put the patient at risk. It does not cover hospitals, Medicaid or TRICARE.
Credit
Texas Legislature
2025
FTC counts specialty markups
On 14 January 2025 the US Federal Trade Commission published its second interim staff report on PBMs, voted 5 to 0. It studied 51 specialty generic drugs, including generic versions of Gleevec for leukaemia and Ampyra for multiple sclerosis, dispensed from 2017 to 2022. Pharmacies owned by the three largest PBMs marked many of them up by hundreds or thousands of percent and took in more than $7.3 billion above their estimated cost of buying the drugs. US only.
Credit
FTC staff
Watch for
States ban PBM-owned pharmacies
Arkansas Act 624 of 2025 says a PBM may not hold a permit for the retail sale of drugs in the state, which would force PBM-owned pharmacies out of Arkansas from 1 January 2026. On 28 July 2025 the federal district court for the Eastern District of Arkansas blocked it before it took effect, finding it likely discriminates against out-of-state companies and is likely preempted by federal TRICARE law. Arkansas appealed to the Eighth Circuit (No. 25-2529), and Tennessee passed a similar ban in May 2026, which PBMs have sued to stop, by the law firm Mintz's account in July 2026. Federal courts have struck state network rules before: in 2023 the Tenth Circuit held that ERISA, the federal law on employer benefit plans, and Medicare Part D preempt Oklahoma's pharmacy distance rules and its any-willing-pharmacy rule, under which a PBM must admit to its preferred network any pharmacy that accepts its terms.
Achieved whenA state ban on PBM-owned pharmacies takes effect and survives appeal.
Claimed by
State of Arkansas, 2025; State of Tennessee, May 2026
Open
01
Open map of drug networks
A free, machine-readable table of every US limited distribution drug and the pharmacies allowed to dispense it, built from drug makers' public pages for prescribers, specialty pharmacies' own published lists and the TRICARE list. Each row carries its source link and the date checked, and a monthly snapshot records which pharmacies were added or dropped.
The briefCredit · unclaimed02
Accredited pharmacies, counted openly
A public list of every accredited specialty pharmacy location in the US, taken from the accreditors' public directories (URAC, ACHC and the Joint Commission), matched to each pharmacy's National Provider Identifier in the federal NPPES registry, and labelled by owner type: PBM-owned, health system, retail chain or independent. It would be refreshed every quarter.
The briefCredit · unclaimed
Open 01 · the brief
Open map of drug networks
The first to publish is credited on this line, and the deliverable moves from Open to Achieved.
What to build
A free, machine-readable table of every US limited distribution drug and the pharmacies allowed to dispense it, built from drug makers' public pages for prescribers, specialty pharmacies' own published lists and the TRICARE list. Each row carries its source link and the date checked, and a monthly snapshot records which pharmacies were added or dropped.
Why it is still open
A subscriber platform, IPD Analytics' Access Hub, tracks these networks; from its data Drug Channels Institute counted 382 specialty drugs with a maker-defined limited or exclusive network in January 2025, 34% of them sold through only one pharmacy, and 164 pharmacies in at least one network. The closest free table is the TRICARE Specialty Program limited distribution list (November 2026), a PDF from Express Scripts that names the pharmacies for more than 130 brands. It covers one military program, keeps no history and is not machine-readable. Pharmacies such as Biologics by McKesson and CVS Specialty publish only their own drug lists. A web and GitHub search found no free table that combines them.
Built with what exists
pdftotext and Python to read the PDFs; a web agent that drives Chrome to read makers' "where to fill" pages, such as Browser Use (see the Note "Deleting 80% to start over"); GitHub Actions for monthly snapshots; a CSV file and a simple static page.
First step
Turn the November 2026 TRICARE PDF into a CSV and check 20 of its drugs against the makers' own pages.
Done looks like
At least 200 drugs, each pharmacy listed with a source link, two reviewers checking 50 random rows against the sources with agreement reported, a published rate of disagreement between sources, and six monthly snapshots with a change log.
Open 02 · the brief
Accredited pharmacies, counted openly
The first to publish is credited on this line, and the deliverable moves from Open to Achieved.
What to build
A public list of every accredited specialty pharmacy location in the US, taken from the accreditors' public directories (URAC, ACHC and the Joint Commission), matched to each pharmacy's National Provider Identifier in the federal NPPES registry, and labelled by owner type: PBM-owned, health system, retail chain or independent. It would be refreshed every quarter.
Why it is still open
Accreditation is a condition of entry to many limited networks, but the main counts, by Drug Channels Institute (553 health-system locations, 28% of the total, in 2025), come from a paid report and only totals are public. URAC's directory sits behind a browser check, and no public file of it was found.
Built with what exists
A web agent that drives Chrome through the directories' search pages, within their terms of use; the NPPES NPI Registry API from CMS; Python for matching; a CSV file on GitHub.
First step
Pull one state's specialty pharmacy listings from each directory by hand and match them to NPIs.
Done looks like
Every location from the three directories listed with its source and date, at least 95% matched to an NPI, owner type checked by two reviewers on 100 random rows with agreement reported, and totals compared with Drug Channels Institute's published 2025 counts.